Lentiviral vector production continues to pose significant challenges for many cell and gene therapy (CGT) developers. Long lead times, high costs, and outdated process models have hindered the scalability and global accessibility to in turn produce these critical therapies. As the CGT field evolves, there is a growing need to rethink how vectors are designed, optimized, manufactured, and delivered, without compromising quality or affordability.
Gain a technical and strategic overview of essential considerations in lentiviral vector development and manufacturing. Drawing on extensive industry experience, experts from Vector BioMed (a leading CVDMO) will share insights into how early decisions in payload design, process control, and model system selection can directly impact vector performance, reproducibility, and time-to-clinic. Also explore are how targeted envelope modifications can enhance T-cell specificity and transduction efficiency, potentially reducing or eliminating the need for stimulation reagents.
Regardless of development stage and with a targeted aim at broader accessibility of advanced therapies, this webinar offers a grounded perspective on navigating requirements and key decisions in vector development to improve efficiencies for global therapies.
Key Takeaways:
- The impact of early-stage decisions, such as payload design, model selection, and process control for more reliable vector performance in clinical and commercial manufacturing of CGTs.
- The role of envelope engineering to improve T-cell targeting and simplify transduction protocols.
- Strategies to identify and overcome legacy assumptions that limit cost-efficiency and scalability in vector production
